Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi® and Epclusa®.
Bioorg Med Chem Lett
; 29(16): 2415-2427, 2019 08 15.
Article
em En
| MEDLINE
| ID: mdl-31230974
ABSTRACT
Direct-acting antiviral inhibitors have revolutionized the treatment of hepatitis C virus (HCV) infected patients. Herein is described the discovery of velpatasvir (VEL, GS-5816), a potent pan-genotypic HCV NS5A inhibitor that is a component of the only approved pan-genotypic single-tablet regimens (STRs) for the cure of HCV infection. VEL combined with sofosbuvir (SOF) is Epclusa®, an STR with 98% cure-rates for genotype 1-6 HCV infected patients. Addition of the pan-genotypic HCV NS3/4A protease inhibitor voxilaprevir to SOF/VEL is the STR Vosevi®, which affords 97% cure-rates for genotype 1-6 HCV patients who have previously failed another treatment regimen.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Inibidores de Proteases
/
Carbamatos
/
Proteínas não Estruturais Virais
/
Hepacivirus
/
Descoberta de Drogas
/
Compostos Heterocíclicos de 4 ou mais Anéis
Limite:
Humans
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article